Exclusive Summary

• - Around 59.7 million people live with AF globally and the number keeps rising; ER BID dosing improves adherence for long-term rhythm control.
• - Key Rythmol SR patents/exclusivities expired circa 2010–2011, leaving no major patent barriers in leading markets.
• - US registration plus FDA-GMP and BE/CTD readiness enable reliance and accelerated registrations across regions.
• - While the US has multiple generics, ER competition remains limited in many countries; three strengths enable 1:1 substitution and tender flexibility.
• - Typical 80–95% savings versus brand provide a clear pharmacoeconomic proposition for payers and hospitals.